| Literature DB >> 33868588 |
Bhaskar Bhattacharya1,2, Daniel Q Huang3,4, Sarah Hong Hui Low1, Gim Hwa Tan1, Min Ji Han1,5, Sanamerjit Singh1,5, Benny Tang1,5, Sheng Chun Chang1,5, Joey Sze Yun Lim1,2, Mohd Feroz Mohd Omar1, Yock Young Dan3,4, Richie Soong1,2,3.
Abstract
The native hepatocellular cancer (HCC) microenvironment is characterized by more hypoxic, hypoglycemic, and acidic conditions than those used in standard cell culture. This study aimed to investigate whether HCC cells cultured in more native conditions have an altered phenotype and drug sensitivity compared to those cultured in standard conditions. Six HCC cell lines were cultured in "standard" (21% O2, 25 mM glucose) or more "native" (1% O2, 5 mM glucose, 10 mM lactate) conditions. Cells were assessed for growth rates, cell cycle distribution, relevant metabolite and protein levels, genome-wide gene expression, mitochondrial DNA sequence and sensitivity to relevant drugs. Many differences in cellular and molecular phenotypes and drug sensitivity were observed between the cells. HCC cells cultured in native conditions had slower doubling times, increased HK2 and GLUT, lower PHDA and ATP levels, and mutations in mitochondrial DNA. Thirty-one genes, including the hypoxia-associated NDRG1, were differentially expressed between the cells. HCC patients in The Cancer Genome Atlas (TCGA) with tumors with a high score based on these 31 genes had a poorer prognosis than those with a low score (p = 0.002). From 90 comparisons of drug sensitivity, increased resistance and sensitivity for cells cultured in native conditions was observed in 14 (16%) and 8 (9%) comparisons respectively. In conclusion, cells cultured in more native conditions can have a more glycolytic and aggressive phenotype and varied drug sensitivity to those cultured in standard conditions, and may provide new insights to understanding tumor biology and drug development. Copyright:Entities:
Keywords: drug development; glycolysis; microenvironment
Year: 2021 PMID: 33868588 PMCID: PMC8021027 DOI: 10.18632/oncotarget.27910
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Cell phenotypes of cells cultured in standard and native conditions.
Cell proliferation evaluated by MTS assay of cells grown in standard (black line) and native (red line) conditions in (A) C3A (B) PLC, (C) SNU449, (D) SKHEP1, (E) HUH7, and (F) HEP3B cells. (G) Cell cycle profile of respective cells grown in standard (STD) and native (NAT) conditions. Data shown as mean ± SD from three independent experiments.
Figure 2Molecular phenotypes of cells cultured in standard and native conditions.
(A) ATP (B) ROS, and (C) lactate production relative to baseline levels, in respective cell lines cultured in native (white bars) and standard (black bars) conditions. Data shown as mean ± SD from three independent experiments.
Figure 3Protein expression of cells cultured in standard and native conditions.
The proteins are grouped according to their roles in glycolysis, glucose transport, PI3K pathway, stress response, and cell death. Also indicated are respective cell lines cultured in native (NAT) and standard (STA) conditions. Representative immunoblots shown of three independent experiments.
Figure 4Gene expression of cells cultured in standard and native conditions.
(A) Fold-change and q-values of the difference in levels of all genes. Analysis was performed from triplicate samples representing each condition. (B) Survival of HCC patients that have dysregulation in the top 31 dysregulated genes (red curve, n = 172) compared to those without (blue curve, n = 199) graphed according to the Kaplan–Meier method. The difference between groups is significant (p = 0.00151).
Genes significantly differentially expressed in cells cultured in native compared to standard conditions, ranked according to p-value
| No | Gene Symbol | Gene Description |
| Difference |
|---|---|---|---|---|
| 1 | NDRG1 | N-myc downstream regulated 1 | 5.51E-08 | 7.836 |
| 2 | PPP1R3C | protein phosphatase 1, regulatory subunit 3C | 1.75E-03 | 2.048 |
| 3 | NEU1 | sialidase 1 (lysosomal sialidase) | 1.80E-03 | 0.429 |
| 4 | PARP3 | poly (ADP-ribose) polymerase family, member 3 | 4.11E-03 | 2.018 |
| 5 | CA9 | carbonic anhydrase IX | 5.35E-03 | 2.611 |
| 6 | PFKFB4 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 | 6.28E-03 | 2.333 |
| 7 | BNIP3L | BCL2/adenovirus E1B 19kDa interacting protein 3-like | 1.09E-02 | 2.408 |
| 8 | DDIT4 | DNA-damage-inducible transcript 4 | 1.97E-02 | 2.298 |
| 9 | FXYD2 | FXYD domain containing ion transport regulator 2 | 1.98E-02 | 2.581 |
| 10 | TXNIP | thioredoxin interacting protein | 2.49E-02 | 2.806 |
| 11 | AK3L1 | adenylate kinase 4 | 2.60E-02 | 2.261 |
| 12 | PNCK | pregnancy up-regulated non-ubiquitously expressed CaM kinase | 2.99E-02 | 3.505 |
| 13 | PLOD2 | procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 | 3.02E-02 | 2.631 |
| 14 | LIMCH1 | LIM and calponin homology domains 1 | 3.17E-02 | 2.650 |
| 15 | RNASET2 | ribonuclease T2 | 4.05E-02 | 2.732 |
| 16 | LEAP2 | liver expressed antimicrobial peptide 2 | 5.73E-02 | 2.297 |
| 17 | WDR54 | WD repeat domain 54 | 9.04E-02 | 2.174 |
| 18 | NDUFA4L2 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 | 1.06E-01 | 2.055 |
| 19 | ANGPTL4 | angiopoietin-like 4 | 1.14E-01 | 2.092 |
| 20 | SLC2A3 | solute carrier family 2 (facilitated glucose transporter), member 3 | 1.52E-01 | 3.640 |
| 21 | LCN15 | lipocalin 15 | 2.04E-01 | 2.860 |
| 22 | LTB | lymphotoxin beta (TNF superfamily, member 3) | 2.04E-01 | 2.298 |
| 23 | KRT80 | keratin 80 | 2.16E-01 | 2.054 |
| 24 | IGFBP1 | insulin-like growth factor binding protein 1 | 2.74E-01 | 2.264 |
| 25 | RELN | reelin | 2.79E-01 | 0.468 |
| 26 | EPDR1 | ependymin related protein 1 (zebrafish) | 3.60E-01 | 2.170 |
| 27 | MT1G | metallothionein 1G | 3.62E-01 | 0.485 |
| 28 | IGFBP3 | insulin-like growth factor binding protein 3 | 6.20E-01 | 2.018 |
| 29 | UBD | ubiquitin D | 6.25E-01 | 2.137 |
| 30 | GC | group-specific component (vitamin D binding protein) | 7.16E-01 | 2.186 |
| 31 | MT2A | metallothionein 2A | 7.89E-01 | 0.478 |
Mitochondrial mutations detected in the HCC cells cultured under native (NAT) and standard (STA) conditions
| Symbol | Gene | Variant | Type | Cell Line |
|---|---|---|---|---|
| MT-RNR2 | mitochondrial ribosomal RNA | 302 A>AC, ACC | insertion | SKHEP1 NAT |
| MT-RNR2 | mitochondrial ribosomal RNA | 302 A>AC, ACC | insertion | SNU449 STA |
| MT-RNR2 | mitochondrial ribosomal RNA | 302 A>AC, ACC | insertion | SNU449 NAT |
| MT-RNR2 | mitochondrial ribosomal RNA | 2487 A>C | SNV | PLC NAT |
| MT-ND1 | Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core | 2487 A>C | SNV | HUH7 NAT |
| MT-ND6 | Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 6 | 16188 CT>C | deletion | HUH7 NAT |
Figure 5Drug sensitivity of cells cultured in standard and native conditions.
The IC50 values of respective drugs (x-axis) of respective cells (respective charts) cultured in native (white bars) and standard (black bars) conditions. An asterisk (*) indicates drugs for which there are significant differences (p < 0.05) in IC50 values between native and standard conditions. Data shown are mean log IC50 ± SD from eight independent experiments.